What is Maze Therapeutics, Inc. Common Stock's revenue?

Maze Therapeutics, Inc. Common Stock (MAZE) generated $187.5M in revenue over the trailing twelve months.

Is Maze Therapeutics, Inc. Common Stock profitable?

Maze Therapeutics, Inc. Common Stock is not currently profitable: it reported a net loss of $122.5M over the trailing twelve months, a -65.4% net margin.

What is Maze Therapeutics, Inc. Common Stock's earnings per share?

Maze Therapeutics, Inc. Common Stock's diluted EPS over the trailing twelve months is $-2.48.

Where does Maze Therapeutics, Inc. Common Stock's income statement data come from?

Every line is extracted from Maze Therapeutics, Inc. Common Stock's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.

Maze Therapeutics, Inc. Common Stock MAZE Income Statement

Income Statement Balance Sheet Cash Flow Ratios Segments

Quarterly Annual TTM

YoY QoQ

Simplified Detailed

	Q1 '26	Q4 '25	Q3 '25	Q2 '25	Q1 '25
Total revenue	$20M—	——	——	$0-100%	——
Research and development	$34.15M+23.8%	$27.57M+24.1%	$25.19M+26.9%	$28.11M+43.8%	$27.58M+26.1%
General and administrative	$12.41M+58.6%	$10.49M+39.7%	$7.78M+13.1%	$8.37M+41.8%	$7.82M+27.4%
Other operating expenses	$46.55M+31.5%	$38.06M+28.0%	$32.97M+23.3%	$36.47M+43.3%	$35.4M+26.4%
Total operating expenses	$46.55M+31.5%	$38.06M+28.0%	$32.97M+23.3%	$36.47M+43.3%	$35.4M+26.4%
Operating income	-$26.55M+25.0%	-$38.06M—	-$32.97M-36.1%	-$36.47M-126%	-$35.4M-26.4%
Operating margin	-132.8%—	——	——	——	——
Interest expense	$866K—	——	——	——	——
Interest income	$3.21M+22.8%	$3.49M+130%	$2.88M+55.9%	$2.8M+176%	$2.62M+831%
Other income (expense), net	$2.35M-10.3%	——	——	——	$2.62M—
Net income	-$24.21M+26.2%	-$34.57M—	-$30.09M-21.6%	-$33.68M-124%	-$32.79M-0.9%
Net margin	-121%—	——	——	——	——
Diluted earnings per share	-$0.45+60.9%	-$0.60-103%	-$0.66+93.6%	-$0.77-124%	-$1.15+91.7%
Basic earnings per share	-$0.45+60.9%	-$0.60-103%	-$0.66+93.6%	-$0.77-113%	-$1.15+91.7%
Weighted-average shares, diluted	53.9M+88.3%	43M+1,474%	45.8M+1,795%	43.8M+915%	28.6M+1,125%
Weighted-average shares, basic	53.9M+88.3%	43M+1,694%	45.8M+1,795%	43.8M+1,733%	28.6M+1,125%
Comprehensive Income (Loss), Net of Tax, Attributable to Parent	-$24.45M+25.4%	-$34.53M—	-$30.02M-21.3%	-$33.68M—	-$32.79M—
Interest income and other, net	$3.21M+22.8%	$3.49M+130%	$2.88M+55.9%	$2.8M+176%	$2.62M+831%
Other income, net (Note 6)	$2.35M-10.3%	——	——	——	$2.62M—
Revenue From Contract With Customer Excluding Assessed Tax	$20M—	——	——	$0-100%	——
EBIT	-$26.55M+25.0%	-$38.06M—	-$32.97M-36.1%	-$36.47M-126%	-$35.4M-26.4%
EBITDA	-$26.11M+24.8%	-$37.56M—	-$32.39M-38.2%	-$35.83M-126%	-$34.72M-28.3%
EBITDA	-$26.11M+24.8%	-$37.56M—	-$32.39M-38.2%	-$35.83M-126%	-$34.72M-28.3%
EBITDA margin	-130.5%—	——	——	——	——
EBIT	-$26.55M+25.0%	-$38.06M—	-$32.97M-36.1%	-$36.47M-126%	-$35.4M-26.4%

Chart any of these lines over time, or line them up against competitors.

Compare these in charts →

Ask your AI about Maze Therapeutics, Inc. Common Stock.

Connect your AI assistant and get a quick read on the numbers, right in your chat.

Connect your AI

Claude

Questions, answered.

What is Maze Therapeutics, Inc. Common Stock's revenue?: Maze Therapeutics, Inc. Common Stock (MAZE) generated $187.5M in revenue over the trailing twelve months.
Is Maze Therapeutics, Inc. Common Stock profitable?: Maze Therapeutics, Inc. Common Stock is not currently profitable: it reported a net loss of $122.5M over the trailing twelve months, a -65.4% net margin.
What is Maze Therapeutics, Inc. Common Stock's earnings per share?: Maze Therapeutics, Inc. Common Stock's diluted EPS over the trailing twelve months is $-2.48.
Where does Maze Therapeutics, Inc. Common Stock's income statement data come from?: Every line is extracted from Maze Therapeutics, Inc. Common Stock's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.